Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023
/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2...